These findings also raised the possibility that, independently of splice site mutations, tumor cells may routinely utilize “conventional” alternative splicing of ATG5 as a mechanism to reversibly regulate ATG12–ATG5-ATG16L1 complex formation and autophagy. The gene discussed is ATG16L1; the disease is neoplasm.